Provention Bio, Inc. Common Stock
PRVB
PRVB was delisted on the 26th of April, 2023.
125 hedge funds and large institutions have $197M invested in Provention Bio, Inc. Common Stock in 2021 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 48 increasing their positions, 32 reducing their positions, and 19 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 32
28% more call options, than puts
Call options by funds: $8.58M | Put options by funds: $6.67M
26% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 19
4% more funds holding
Funds holding: 120 → 125 (+5)
21% less capital invested
Capital invested by funds: $248M → $197M (-$51.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VA
VR Adviser
New York
|
+$23.4M |
| 2 |
SC
Sessa Capital
New York
|
+$22.5M |
| 3 |
State Street
Boston,
Massachusetts
|
+$1.96M |
| 4 |
Millennium Management
New York
|
+$1.84M |
| 5 |
PPA
Parametric Portfolio Associates
Seattle,
Washington
|
+$1.79M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GGHC
Gilder Gagnon Howe & Co
New York
|
-$22.8M |
| 2 |
PA
Perceptive Advisors
New York
|
-$15.4M |
| 3 |
Two Sigma Advisers
New York
|
-$7.16M |
| 4 |
Two Sigma Investments
New York
|
-$4.04M |
| 5 |
6CM
683 Capital Management
New York
|
-$2.68M |
PRVB Hedge Fund Activity: Q2 2021 in Review
125 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Provention Bio, Inc. Common Stock (PRVB) for Q2 2021, worth a combined $197M — down 21% from $248M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new PRVB positions and 19 closed out — a net gain of 5 holders — while 48 added to existing stakes and 32 trimmed.
The largest buyer was VR Adviser, opening a new position worth an estimated $23.4M. The largest seller was Gilder Gagnon Howe & Co, cutting an estimated $22.8M.
- 125 institutional investors held Provention Bio, Inc. Common Stock (PRVB) as of Q2 2021, up from 120 in Q1 2021.
- Funds reported $197M of Provention Bio, Inc. Common Stock stock for Q2 2021, down 21% quarter-over-quarter.
- 24 funds opened new Provention Bio, Inc. Common Stock positions in Q2 2021 and 19 closed out, a net change of +5 holders.
- The largest Provention Bio, Inc. Common Stock buyer in Q2 2021 was VR Adviser, an estimated $23.4M added.
- The largest Provention Bio, Inc. Common Stock seller in Q2 2021 was Gilder Gagnon Howe & Co, an estimated $22.8M sold.
Based on aggregated 13F filings for Q2 2021.